Therapeutic Effect of New Biologics in Crohn's Disease
Status
Conditions
Details and patient eligibility
About
New types of biologics have brought advantages in therapy strategies for Crohn's disease. However, clinical data evaluating their efficacy and adverse in China is lacking. We aimed to evaluate the short-term and long-term therapeutic effect as well as drug adverse of Ustekinumab (UST) and Vedolizumab (VED). Besides, we aim to figure out the independent factors predicting the effectiveness of new biologics. Relations between drug exposure (trough concentration and antibody concentration) and therapeutic efficacy are study in-depth by this retrospective observational study.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Consecutive adult patients with confirmed diagnosis of Crohn's disease and administration of new type biologics.
Exclusion criteria
- loss of follow-up, incomplete clinical data, without confirmed diagnosis
Trial contacts and locations
Loading...
Central trial contact
Jiayin Yao
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal